Novartis AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
- Introduction
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
Extension Study of Enteric-coated Mycophenolate Sodium in Combination With Full Dose or Reduced Dose Cyclosporine Microemulsion in Patients With de Novo Kidney Transplants
Phase 3
Completed
- Conditions
- Renal Transplantation
- First Posted Date
- 2005-10-14
- Last Posted Date
- 2011-01-31
- Lead Sponsor
- Novartis
- Target Recruit Count
- 55
- Registration Number
- NCT00238940
Efficacy and Safety of Enteric-Coated Mycophenolate Sodium (EC-MPS) in Renal Transplant Patients
Phase 4
Completed
- Conditions
- Kidney Transplantation
- Interventions
- First Posted Date
- 2005-10-14
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 40
- Registration Number
- NCT00239083
- Locations
- 🇨🇭
Novartis, Basel, Switzerland
Efficacy and Safety of Basiliximab in Hepatitis C Virus Positive Patients Undergoing Liver Transplantation
Phase 3
Completed
- Conditions
- Liver Transplant
- First Posted Date
- 2005-10-14
- Last Posted Date
- 2010-09-01
- Lead Sponsor
- Novartis
- Target Recruit Count
- 194
- Registration Number
- NCT00238901
Study of Enteric-Coated Mycophenolate Sodium (EC-MPS) Plus Reduced-dose Cyclosporine Microemulsion (CsA-ME) Compared to EC-MPS Plus Standard Dose CsA-ME in Eldery de Novo Renal Transplant Recipients Treated With Basiliximab and Short-term Steroids
Phase 3
Completed
- Conditions
- Denovo Renal Transplantation
- Interventions
- First Posted Date
- 2005-10-14
- Last Posted Date
- 2011-01-31
- Lead Sponsor
- Novartis
- Target Recruit Count
- 117
- Registration Number
- NCT00239031
Extension Study to Assess Tolerability and Safety of Enteric-coated Mycophenolate Sodium in Renal Transplant Recipients Who Received Mycophenolate Mofetil
Phase 4
Completed
- Conditions
- Renal Transplantation
- First Posted Date
- 2005-10-14
- Last Posted Date
- 2011-01-31
- Lead Sponsor
- Novartis
- Target Recruit Count
- 187
- Registration Number
- NCT00238966
Study of Enteric-coated Mycophenolate Sodium Maintenance Therapy in Patients With Renal Transplant Receiving Cyclosporine Microemulsion and Steroids,
Phase 3
Completed
- Conditions
- Maintenance Renal Transplantation
- First Posted Date
- 2005-10-14
- Last Posted Date
- 2011-01-31
- Lead Sponsor
- Novartis
- Target Recruit Count
- 23
- Registration Number
- NCT00239057
Extension Study on the Efficacy and Safety of Enteric-coated Mycophenolate Sodium Administered in de Novo Kidney Transplant Patients
Phase 4
Completed
- Conditions
- De Novo Kidney Transplantation
- First Posted Date
- 2005-10-14
- Last Posted Date
- 2011-01-31
- Lead Sponsor
- Novartis
- Target Recruit Count
- 144
- Registration Number
- NCT00239018
Extension Study on the Safety and Efficacy of Enteric-coated Mycophenolate Sodium in Kidney Transplant Recipients
Phase 3
Completed
- Conditions
- Renal Transplantation
- First Posted Date
- 2005-10-14
- Last Posted Date
- 2011-01-31
- Lead Sponsor
- Novartis
- Target Recruit Count
- 69
- Registration Number
- NCT00239070
Efficacy and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in de Novo Kidney Transplant Recipients
Phase 4
Completed
- Conditions
- Renal Transplantation
- Interventions
- First Posted Date
- 2005-10-14
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 30
- Registration Number
- NCT00238953
- Locations
- 🇨🇭
Novartis, Basel, Switzerland
A Clinical Study to Assess the Efficacy and Safety of Vildagliptin in Patients With Type 2 Diabetes
Phase 2
Completed
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2005-10-13
- Last Posted Date
- 2012-05-02
- Lead Sponsor
- Novartis
- Target Recruit Count
- 291
- Registration Number
- NCT00238498